One can envision combining KPT−8602 with an exon-skipping PMO or a μ-dystrophin adeno-associated viral gene therapy strategy to strengthen the myofiber membrane integrity while blocking inflammatory signaling and immune cell infiltration in DMD muscles. This evidence concerns the gene DMD and Duchenne muscular dystrophy.